Optomed - Health technology company

This gambling market is nothing new for Optomed. In my opinion, they’ve had a contract with Veikkaus before as well, no one just ever told you about it. Revenue has apparently come through software. Those who know better can correct me if I’m wrong. Now the situation is even better, as dozens of companies are applying for the Finnish gambling market and Ubutec is the only one that has done so in Finland, as far as I know.

7 Likes

The spin-off was done precisely because Optomed’s core business remains fundus cameras. Ubetec focuses on the gaming market with its own personnel and strategy. Ubetec’s packaging is downright ingenious (cooperating with Nordic Legal Hero) where they consult and implement the technical platform at the same time.

If there have been around 51 license applicants for the Finnish market, and say half of them get a license, and half of those (?) need Ubetec as their technical partner, then in the coming years that could generate about 10 x €0.9M (I used Veikkaus’s contract as a baseline) in revenue, which is significant operational growth for the scale of the Optomed group.

But from an investment perspective, let’s just focus on how the cash is running out next week and a profit warning (negari) is coming any second now.

19 Likes

It looks like there are at least 57 applicants.

Spinning off the gambling supervision into its own company is completely normal, logical, and sensible. The reasons include industry differences, reporting, and different business growth prospects. In this particular business, the near-term growth outlook is indeed remarkable, and operations are sure to be very profitable. According to the article in the link, the processing time for licenses is six months, so if a new operator wants to start right when the market opens on July 1, 2026, a business like Ubetec has busy times ahead.

9 Likes

[quote=“Sheikki, post:6734, topic:2389”]
There seems to be at least 57 applicants.

[/quote>

Or perhaps as many as 64?

6 Likes

Could this be the implementation of Optomed’s “playbook”. It still bothers me why Optomed changed its reporting method some time ago, and could this be the reason for it?

Ubetec: Balance sheet protection and cash flow buffer

  • Recurring SaaS revenue: Ubetec’s contracts (such as Veikkaus’s 0.9 million euro two-year contract and the market’s 64 potential license applicants) are recognized over time. Continuous data vaulting and regulatory reporting will bring predictable, high-margin cash flow starting from 2027.

  • Non-dilutive financing: The RegTech business will act as an efficient internal funding source in the near future, reducing the need for share issues that erode shareholder value. It covers the group’s fixed costs and provides peace of mind for the commercialization of health technology.

Business Area Role in Portfolio Nature of Revenue Market Target
Ubetec (RegTech) Cash flow machine & balance sheet support Recurring SaaS / ARR (pro-rated) Finland 2026–2028 (64 operators)
Aurora AEYE (MedTech) Valuation multiple scaler Hardware + recurring AI service United States & global markets

The market has long priced high risk into Optomed due to slowly progressing device sales and cash adequacy. In my view, if successful, Ubetec removes the immediate balance sheet/cash risk by bringing predictable and high-margin revenue. That upcoming deal with Veikkaus announced on Friday was a fantastic opening move, and a large portion of those 64 license applicants will likely seek out a player that has even been involved in drafting future regulation and operates in a very strong alliance.

In addition, for an international operator unfamiliar with Finnish regulatory practices, choosing Ubetec is the safest route to avoid violating license conditions. The company’s background as a provider of regulatory statements and Optomed Software’s regulatory expertise remove regulatory risk from the operators.

4 Likes

Since I don’t have the expertise to assess the financial impact/leverage, a quick brainstorming session with AI produced this table. Does anyone have the expertise/ability to assess whether it’s at all in line?

In the software-based RegTech business, the operating leverage is exceptionally steep because the development costs for the regulatory platform (Ubetec Vault, DQ-Engine, and regulatory interfaces) are largely fixed and have already been incurred. Onboarding a new operator to the ready-made cloud infrastructure costs Ubetec only a fraction of the license fee received.

Nature of the Cost Structure in the RegTech Model

  • Fixed Costs (estimated at €1.0–1.5M / year): Maintenance of the core architecture, regulatory updates, audits/cybersecurity certifications, and a 6–10 person technical and legal core team. These costs run regardless of whether there are 2 or 25 customers.

  • Variable Costs per Customer (10–15% of revenue): Cloud capacity (AWS/Azure storage and computing in the data vault), deployment expert support, and customer-specific interface testing.

  • Incremental EBITDA (EBITDA Leverage): Once the fixed cost base is covered, an estimated 70 to 85 cents of every new euro of revenue flows straight to EBITDA.

Profitability and Earnings Leverage in Various Scenarios

Assuming Ubetec’s fixed costs are €1.2M per year and variable costs are 15% of revenue:

Scenario Number of Customers & Average Billing Annual Revenue Costs (Fixed + Variable) Ubetec EBITDA EBITDA-%
Zero Level Veikkaus only (€450k) €0.45M €1.27M -€0.82M Loss-making
Break-even Veikkaus + 5 small operators (~€160k) €1.45M €1.42M +€0.03M ~2%
Base Case Outcome Veikkaus + 12 operators (total 20% of market) €2.85M €1.63M +€1.22M 43%
Strong Success Veikkaus + 20 operators (~30% of market) €4.45M €1.87M +€2.58M 58%
Bull Scenario Veikkaus + 30 operators (~50% of market) €6.45M €2.17M +€4.28M 66%

What Does This Mean for the Entire Optomed Group?

  • Group-wide Earnings Turnaround: Optomed Group’s revenue has hovered around the €15M level, and the result has been loss-making or close to break-even due to clinical trials on the device side and building international sales. Ubetec’s contribution of €2.5–4.0 million in EBITDA would permanently turn the entire listed company’s net profit positive.

  • Cash Flow Profile Change: In SaaS agreements, billing typically happens in advance (annual or quarterly invoicing). This brings front-loaded working capital and minimizes the group’s financing risk.

  • Valuation Multiples: A loss-making device manufacturer is priced at low EV/Sales multiples, but a high-margin (over 50% EBITDA) recurring-revenue B2B software company commands a high earnings-based multiple in the market (e.g., EV/EBITDA 15–25x). Ubetec’s operating profit alone could then justify Optomed’s entire current market capitalization.

3 Likes

[quote="Mr_Stock, post:6736, topic:2389"]\ninvestment in the Ubetec business, which produced its first contract 9 months later.\n[/quote]\n\nUbetec, which was founded in 9/2024, of course already had prior business before this Veikkaus contract. Coincidentally, in that same month of 9/2024, a multi-year €10M contract related to gambling supervision was signed with the National Police Board (Poliisihallitus), which is undoubtedly now part of Ubetec’s financial statements. Ubetec could very well be the cash flow savior for Optomed over the next couple of years, after which health technology will stand on its own feet, and Ubetec will be sold. After all, Ubetec fits in with Optomed’s health tech image about as well as military-grade rubber boats once fit in with Revenio.\n\nhttps://forum.inderes.com/t/optomed-terveysteknologiayhtio/2389/2712\n\nhttps://tietopalvelu.ytj.fi/yritys/3473198-7

7 Likes

Now that’s mixing apples and oranges if the same company provides both the regulatory software and the software that complies with it. Isn’t the Police Board deal an Optomed Software case (different Business ID [y-tunnus] too)? Plus, that VAT liability has only been “on”, so to speak, for a short time.

If the market opens at the turn of the year, hardly any operator will be able to start operations without its compliance infrastructure (such as the Ubetec Vault data collection vault and responsible gaming reporting APIs) being not only coded, but also tested and audited in accordance with the requirements of the new Finnish supervisory authority. Such an IT integration is not done in weeks. The decision on a partner must be made in the autumn so that the systems are ready for testing in December.

License processing bottleneck: the authority will likely demand during the license process, or as a condition for starting operations, proof of how the operator intends to technically implement the required supervision. Foreign giants (e.g., Betsson, Kindred, Bet365) are in a hurry to lock in the name of a local partner (such as Ubetec or Nordic Legal) with which they will prove their technical capability to the authority.

The Veikkaus deal might be a “ketchup bottle effect”. When Veikkaus announced on Friday, September 4, 2026, that it had chosen Ubetec, it actually, in my opinion, made the company the de facto standard of the market. When a foreign listed company’s compliance director weighs the risks of entering the new Finnish market, the safest choice is to pick the same operator that has been deemed acceptable by the Finnish state-owned company and has also been involved in drafting the law.

The next 1–3 months (September–November 2026) are therefore likely the moment of truth for Ubetec. If Ubetec is the “one-stop shop” in the market that it promises to be, it should start announcing (or Optomed should report in its interim reports) new operator agreements very soon. If nothing else is heard by the end of the year besides Veikkaus, then it went down the drain, so to speak…

16 Likes

Q2 2026 Inderes interview and starting from 7:30 => “we have several competitive bidding processes ongoing that we are participating in, and with a high probability, we will win some of them. That means during the H2 half, there will be major delivery projects and through that also larger invoicing in addition to daily invoicing.” What could they be talking about here?

7 Likes

Millions in cash are coming to Veikkausliiga and the clubs from new gambling companies. Ubetec’s 0.5-1M project (and the ongoing annual revenue after that) is peanuts in the big picture for a new entrant. The essential thing is to get the operation working right away. Not many companies are capable of that, let alone offer a corresponding service in the Finnish market.

28 Likes

Here are Juha’s comments on how Optomed’s subsidiary Ubetec Oy won Veikkaus Oy’s competitive bidding process. :slight_smile:

Optomed announced on Friday that its subsidiary Ubetec Oy has won the competitive bidding process regarding Veikkaus Oy’s gaming compliance services. The total value of the contract is estimated at approximately EUR 0.9 million over a two-year period, averaging around EUR 0.45 million annually. According to the company, only a small portion of the total contract value will be recognized as revenue in 2026. The procurement decision is not yet legally binding (the appeal period is ongoing), and the agreement between the parties has not yet been signed. We consider the news slightly positive for Optomed, as it strengthens Ubetec’s position in Finland’s opening gambling market.

23 Likes

Things are happening in China…

13 Likes

Optomed doesn’t seem to be involved in those trade fairs, that Wiiser has many other irons in the fire there.

Finland is specifically mentioned (to the market square!) and Kevin Cheng is also specifically mentioned as being at the stand, and Kevin is, after all, the “director” of Wiser Optomed. I could place it under Optomed’s “digital innovation” since they have even won awards in China.

Not that there aren’t plenty of these ribbon-cutting events, and rightly so. Although when Optomed announces it has won a gaming regulation procurement tender from a Finnish monopoly company, the stock drops by a percent the next day. You can accumulate shares in peace, no need to cry out later “if only I had…”

Quite a peculiar comment left by a Commit employee on Niklas Bondestam’s post about the theme of less than 300 days until the market opens. “Who might be the one holding the dynamite​:grinning_face:”

=> looks like he’s right in the middle of it: Project lead for over 12 years converting the Finnish gambling regulatory legal requirements into working technical solutions @commit.ficommit.ficommit.ficommit.fi

16 Likes

Hopefully they make new deals over there.

9 Likes

Aeye Health has finally published the results of its FDA trials.

..
“The data from AEYE-DS’s three clinical trials speak for themselves. AEYE-DS finally makes diabetic eye exams practical at the point of care: portable and tabletop devices, just one image per eye, no dilation, and best-in-class diagnostic efficacy. No other FDA-cleared solution does any of that,” said Dr. Zack Dvey-Aharon, Ph.D., Co-Founder and CEO of AEYE Health. “With this groundbreaking clinical evidence, a screening workflow that can be completed by staff members in just one minute, and seamless EHR integration, we expect AEYE-DS to continue its rapid expansion across the United States and become the new American standard for diabetic eye exams.”
..

32 Likes

Then we need a couple of know-it-alls to tell the rest of us how a laptop loses to a desktop and how multiple photos have to be taken before one is good enough for AI analysis.

Let’s skip this round this time.

13 Likes

It’s easy to agree with this. Can anyone estimate why the study is only being published now + how one could get access to the very latest usage statistics for the 92229 reimbursement codes @usa? Currently, the data is from 2023, and to put it politely, it was practically non-existent…